Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.

Published

Journal Article

BACKGROUND: Serum Chromogranin A (CgA) is widely used as a biomarker for pancreatic neuroendocrine tumors (PanNETs). The aim of this study was to investigate the value of CgA as a diagnostic and prognostic marker for well-differentiated PanNETs. METHODS: Patients with well-differentiated PanNET and a baseline CgA measurement, between 2011 and 2016 were reviewed. The diagnostic value was determined by comparing CgA values from patients with PanNETs to those with other pancreatic neoplasms and healthy controls. The Kaplan-Meier method was used to investigate the CgA prognostic significance. RESULTS: Ninety-nine patients met inclusion criteria. As a diagnostic marker, CgA had a sensitivity of 66%, specificity of 95%, and overall accuracy of 71%. The use of PPIs was associated with a higher CgA level (p = 0.015). When excluding patients on PPIs, CgA accuracy in distinguishing PanNETs from other pancreatic neoplasms was 66%, the sensitivity and specificity were 60% and 75% respectively. Elevated CgA (p = 0.004), Ki67% (p < 0.001), tumor grade (p < 0.001) and stage of disease (p = 0.036) were associated with disease-specific survival. CONCLUSION: CgA has a limited role as a diagnostic biomarker for well-differentiated PanNETs. An elevated CgA level may have prognostic value but its role should be further investigated with respect to other known pathological factors.

Full Text

Duke Authors

Cited Authors

  • Pulvirenti, A; Rao, D; Mcintyre, CA; Gonen, M; Tang, LH; Klimstra, DS; Fleisher, M; Ramanathan, LV; Reidy-Lagunes, D; Allen, PJ

Published Date

  • May 2019

Published In

Volume / Issue

  • 21 / 5

Start / End Page

  • 612 - 618

PubMed ID

  • 30366884

Pubmed Central ID

  • 30366884

Electronic International Standard Serial Number (EISSN)

  • 1477-2574

Digital Object Identifier (DOI)

  • 10.1016/j.hpb.2018.09.016

Language

  • eng

Conference Location

  • England